TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson. | May 10, 2023
03.05.2023 - Continued Innovation Across Platforms Facilitates Current Pipeline Advancements and Increases Opportunities for Future Pipeline CandidatesSOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) - Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a . Seite 1